ClinicalTrials.gg
CompletedNCT06979973Updated Feb 27, 2026

A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants

A Phase 1 interventional study of Midazolam and Rosuvastatin in Healthy, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Phase 1, open-label, non-randomized, three-treatment, one-sequence interaction study to evaluate the PK interactions between CKD-508, midazolam, and rosuvastatin in healthy adult male participants

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is capable of providing signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and the protocol.
  • Male adults aged 18 to 45 years at screening.
  • Healthy participants were determined by pre-study medical evaluation and judged by the Investigator.
  • Non-smoker (or other nicotine use) as determined by history (no nicotine use over the past 6 months) and by urine cotinine concentration (\<200 ng/mL) at screening and admission.

Exclusion criteria

Exclusion Criteria:

  • History or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder as determined by the Investigator.
  • Presence of any disorder that would interfere with the absorption, distribution, metabolism, or excretion of study intervention as judged by the Investigator.
  • Serum alkaline phosphatase (ALP) or total ≥ (ULN), or (ALT) or aspartate aminotransferase (AST) >ULN at either screening or admission.
  • Abnormal renal function with estimated (eGFR) \<80 mL/min/1.73 m2 at screening.
  • History or presence of clinically significant abnormal cardiac automaticity, heart rhythm, findings, or other relevant conditions that may pose a risk to the participants as judged by the Investigator.
  • Resting heart rate ≥100 bpm or \<50 bpm at screening or admission.
  • Resting systolic blood pressure ≥140 mmHg and /or diastolic blood pressure ≥90 mmHg at screening or admission.
  • Evidence of known risk factors for atrial fibrillation (eg, smoking, hyperthyroidism, diabetes)
  • History of alcohol and/or illicit drug abuse within 2 years before screening or positive urine test for alcohol or positive urine drug test at screening or admission.
  • Positive test for , , or antibody at screening.
  • Donation of blood (>500 mL) or blood products within 2 months prior to dosing.
  • Use of over-the-counter medications (including vitamins), prescription medications, or herbal remedies within 14 days or 5 half-lives, whichever is longer, prior to dosing.
  • Receiving an drug within 30 days or >5 half-lives of the investigational drug, whichever is longer, prior to dosing.
  • History of to CETP inhibitor or statins or midazolam or to medicinal products with similar chemical structures.
  • Individual unlikely to comply with the protocol requirements, instructions, and study-related restrictions.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Midazolam, Rosuvastatin, CKD-508

    Single dose of Midazolam Single and Multiple dose of Rosuvastatin Multiple dose of CKD-508

    Drug: Midazolam · Drug: Rosuvastatin · Drug: CKD-508 Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax of midazolam

    Maximum plasma concentrations of midazolam after single dose

    Time frame: 24 hours

  2. AUClast of midazolam

    Area under the concentration-time curve of midazolam after single dose

    Time frame: 24 hours

  3. AUCinf of midazolam

    Area under the concentration-time curve extrapolated to infinity of midazolam

    Time frame: From 0 hours to 24 hours on Day 1 and Day 24

  4. Cmax of Rosuvastatin

    Maximum plasma concentrations of rosuvastatin after single dose

    Time frame: 72 hours

  5. AUClast of rosuvastatin

    Area under the concentration-time curve of rosuvastatin after single dose

    Time frame: 72 hours

  6. AUCinf of rosuvastatin

    Area under the concentration-time curve extrapolated to infinity of rosuvastatin

    Time frame: From 0 hours to 72 hours on Day 1 and Day 24

  7. Cmax,ss of CKD-508

    Maximum plasma concentration at steady state of CKD-508

    Time frame: 24 hours

  8. AUCtau,ss of CKD-508

    Area under the concentration time curve until the end of dosing interval at steady state of CKD-508

    Time frame: 24 hours

  9. Cmin,ss of CKD-508

    Minimum plasma concentration at steady state of CKD-508

    Time frame: 24 hours

07

Study locations

1 site
  • Research Site
    Glendale, California 91206, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Aug 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 20, 2025
StartActual
May 14, 2025
Primary completionActual
Aug 17, 2025
CompletionActual
Aug 17, 2025
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06979973
Responsible party
Sponsor
First posted
May 20, 2025
Start date
May 14, 2025
Primary completion
Aug 17, 2025
Completion
Aug 17, 2025
Last update
Feb 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CKD-508

Start the discussion